SCHEDULE 13G/A: Tang Capital Group Discloses 7.80% Stake in Reviva Pharmaceuticals Holdings, Inc.

Tang Capital Management, LLC and its affiliated entities, including Kevin Tang, have disclosed a combined beneficial ownership of 7.80% in Reviva Pharmaceuticals Holdings, Inc., totaling 3,910,304 shares, including those exercisable via warrants.

Summary

• Tang Capital Management, LLC, Kevin Tang, and affiliated entities (Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc.) collectively reported beneficial ownership of 3,910,304 shares of Reviva Pharmaceuticals Holdings, Inc. common stock.
• This represents 7.80% of the company's outstanding common stock.
• The reported ownership includes 510,329 shares of common stock and 3,399,975 shares currently issuable upon the exercise of warrants.
• The percentage is calculated based on 50,139,924 total outstanding shares, which includes 46,739,949 shares outstanding as of March 14, 2025, plus the 3,399,975 shares from warrants.
• The Investor Warrants held by Tang Capital Partners, LP are immediately exercisable for 0.75 of a share of common stock and expire five years from their issuance date.
• A 9.99% ownership limitation applies to warrant exercise, which can be increased to 19.99% with 61 days prior written notice to the Issuer.
• All reporting persons share voting and dispositive power over their respective holdings.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a routine disclosure of a significant ownership stake, which can be seen as a vote of confidence from the investor. However, it contains no new operational or financial news about the company.

Positives

• Significant institutional investment by Tang Capital, indicating confidence in Reviva Pharmaceuticals Holdings, Inc.'s prospects.
• The ability to exercise warrants for additional shares provides flexibility for increasing their stake in the future, up to 19.99% with proper notice.

Risks

• Potential dilution for existing shareholders if the 3,399,975 warrants are fully exercised, increasing the total outstanding shares.
• The 9.99% ownership cap on warrant exercise (and potential increase to 19.99%) could limit the immediate influence or control Tang Capital can exert without further notice or action.

Future Outlook

N/A This is a beneficial ownership filing and does not contain forward-looking statements or guidance from the issuer.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11."

Industry Context

This filing indicates a significant passive investment by a capital management group in a pharmaceutical company. Such investments are common in the biotech and pharmaceutical sectors, where long-term capital is often deployed in companies with promising drug pipelines or intellectual property. The nature of the investment (including warrants) suggests a strategic, yet currently non-controlling, interest in Reviva Pharmaceuticals Holdings, Inc.

Comparison to Industry Standards

• This is a Schedule 13G filing, which reports beneficial ownership. It does not contain operational or financial results that can be directly compared to industry standards or specific comparable companies/projects.
• The ownership percentage of 7.80% is a substantial minority stake, typical for institutional investors seeking exposure without control, especially in growth-oriented sectors like pharmaceuticals.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor (Tang Capital) holding 7.80% of shares, including warrants, could be viewed positively as a sign of investor confidence. There is potential for future dilution if the warrants are fully exercised.
• Management: Awareness of a significant shareholder group with shared voting and dispositive power, though the filing states the purpose is not to change or influence control beyond potential nominations.

Key Dates

Recommendation

Keywords

Reviva Pharmaceuticals Holdings, Inc., Tang Capital Management, LLC, Kevin Tang, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, pharmaceutical, biotechnology